Reduction in 18F-fluorodeoxyglucose uptake on serial cardiac positron emission tomography is associated with improved left ventricular ejection fraction in patients with cardiac sarcoidosis

Journal of Nuclear Cardiology

Volumn 21, Issue 1, 2014, Pages 166-174

  Osborne, Michael T ^a   Hulten, Edward A ^a   Singh, Avinainder ^b   Waller, Alfonso H ^a   Bittencourt, Marcio S ^a   Stewart, Garrick C ^a   Hainer, Jon ^a   Murthy, Venkatesh L ^c   Skali, Hicham ^a   Dorbala, Sharmila ^a   Di Carli, Marcelo F ^a   Blankstein, Ron ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b GOVERNMENT MEDICAL COLLEGE AND HOSPITAL   (India)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

cardiomyopathy; fluorodeoxyglucose (FDG); metabolism; PET; PET imaging

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; FLUORODEOXYGLUCOSE F 18; RUBIDIUM 82; RADIOPHARMACEUTICAL AGENT; RUBIDIUM;

ADULT; ARTICLE; CLINICAL ARTICLE; DOUBLE BLIND PROCEDURE; FEMALE; HEALTH CARE; HEART EJECTION FRACTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; IMAGE ANALYSIS; MALE; MIDDLE AGED; MYOCARDIAL PERFUSION IMAGING; MYOCARDITIS; PET-CT SCANNER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SARCOIDOSIS; TREATMENT RESPONSE; CARDIOMYOPATHY; CHEMISTRY; HEART; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE; INFLAMMATION; LONGITUDINAL STUDY; PATHOLOGY; PERFUSION; PROCEDURES; SCINTISCANNING; TREATMENT OUTCOME;

ADRENAL CORTEX HORMONES; ADULT; CARDIOMYOPATHIES; FEMALE; FLUORODEOXYGLUCOSE F18; HEART; HUMANS; INFLAMMATION; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MYOCARDIUM; PERFUSION; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RUBIDIUM RADIOISOTOPES; SARCOIDOSIS; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT;

EID: 84893823584     PISSN: 10713581     EISSN: 15326551     Source Type: Journal    
DOI: 10.1007/s12350-013-9828-6     Document Type: Article

References (18)

1. Iannuzzi MC, Fontana JR. Sarcoidosis: Clinical presentation, immunopathogenesis, and therapeutics. J Am Med Assoc 2011;305:391-9.
2. Silverman KJ, Hutchins GM, Bulkley BH. Cardiac sarcoid: A clinicopathologic study of 84 unselected patients with systemic sarcoidosis. Circulation 1978;58:1204-11. (Pubitemid 9092005)
3. Yazaki Y, Isobe M, Hiroe M, Morimoto S, Hiramitsu S, Nakano T, et al. Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone. Am J Cardiol 2001;88:1006-10. (Pubitemid 33042612)
4. Schliamser JE, Kadish AH, Subacius H, Shalaby A, Schaechter A, Levine J, et al. Significance of follow-up left ventricular ejection fraction measurements in the Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation trial (DEFINITE). Heart Rhythm 2013;10:838-46.
5. Chiu CZ, Nakatani S, Zhang G, Tachibana T, Ohmori F, Yamagishi M, et al. Prevention of left ventricular remodeling by long-term corticosteroid therapy in patients with cardiac sarcoidosis. Am J Cardiol 2005;95:143-6. (Pubitemid 40051133)
6. Grutters JC, van den Bosch JM. Corticosteroid treatment in sarcoidosis. Eur Respir J 2006;28:627-36. (Pubitemid 44794680)
7. Nery PB, Leung E, Birnie DH. Arrhythmias in cardiac sarcoidosis: Diagnosis and treatment. Curr Opin Cardiol 2012;27:181-9.
8. Youssef G, Beanlands RS, Birnie DH, Nery PB. Cardiac sarcoidosis: Applications of imaging in diagnosis and directing treatment. Heart 2011;97:2078-87.
9. Blankstein R, Osborne M, Naya M, Waller A, Kim CK, Murthy VL, et al. Cardiac positron emission tomography enhances prognostic assessments of patients with suspected cardiac sarcoidosis. J Am Coll Cardiol 2013. doi: 10.1016/j.jacc.2013.09.022.
10. Okumura W, Iwasaki T, Toyama T, Iso T, Arai M, Oriuchi N, et al. Usefulness of fasting 18F-FDG PET in identification of cardiac sarcoidosis. J Nucl Med 2004;45:1989-98. (Pubitemid 47611626)
11. Ohira H, Tsujino I, Yoshinaga K. (1)F-Fluoro-2-deoxyglucose positron emission tomography in cardiac sarcoidosis. Eur J Nucl Med Mol Imaging 2011;38:1773-83.
12. Dorbala S, Vangala D, Sampson U, Limaye A, Kwong R, Di Carli MF. Value of vasodilator left ventricular ejection fraction reserve in evaluating the magnitude of myocardium at risk and the extent of angiographic coronary artery disease: A 82Rb PET/CT study. J Nucl Med 2007;48:349-58. (Pubitemid 47604916)
13. Kida K, Yoneyama K, Kobayashi Y, Takano M, Akashi YJ, Miyake F. Late gadolinium enhancement on cardiac magnetic resonance images predicts reverse remodeling in patients with nonischemic cardiomyopathy treated with carvedilol. Int J Cardiol 2013;168:1588-9.
14. Lower EE, Baughman RP. Prolonged use of methotrexate for sarcoidosis. Arch Intern Med 1995;155:846-51.
15. Schuller JL, Zipse M, Crawford T, Bogun F, Beshai J, Patel AR, et al. Implantable cardioverter defibrillator therapy in patients with cardiac sarcoidosis. J Cardiovasc Electrophysiol 2012;23:925-9.
16. Betensky BP, Tschabrunn CM, Zado ES, Goldberg LR, Marchlinski FE, Garcia FC, et al. Long-term follow-up of patients with cardiac sarcoidosis and implantable cardioverter-defibrillators. Heart Rhythm 2012;9:884-91.
17. Boellaard R. Need for standardization of 18F-FDG PET/CT for treatment response assessments. J Nucl Med 2011;52:93S-100S.
18. Boellaard R. Standards for PET image acquisition and quantitative data analysis. J Nucl Med 2009;50:11S-20S.